Volume 186 - Issue 9
The National Prescribing Service should lead
Author: Jim R Stockigt
Med J Aust 2007; 186 (9): 484. || doi: 10.5694/j.1326-5377.2007.tb01009.x
Published online: 7 May 2007
Published online: 7 May 2007
In reply: It is encouraging that Donohoo, on behalf of MIMS, supports initiatives to more regularly update product information (PI). My review1 demonstrates that necessity. The material published by MIMS is apparently not under their direct editorial control; it depends on PI from the pharmaceutical industry, vetted by the Therapeutic Goods Administration. Revision of PI by drug sponsors has major inertia.2
While the problems in the thyroid area can be serious for a fraction, perhaps 1%–2% per year, of the 200 000 people who take thyroid medications, I made no assertion that the deficiencies identified for thyroid-related medications reflect other PI-based information; that question remains open.
Donohoo emphasises that the PI-based information in MIMS is not a stand-alone resource for health professionals, who are able to choose between sources of drug information. By contrast, consumers are offered PI-based consumer medicine information (CMI) as a definitive resource, without choice. The obligatory link between PI and CMI3 is a compelling reason for revision of PI.
In my view, the National Prescribing Service, an organisation that publishes the journal Australian Prescriber and fosters quality use of medicines, is the national resource best placed to show initiative to improve the current deplorable state of thyroid-related PI which is, in my view, an impediment to safe, well informed health care for some thousands of Australians. Together with Donohoo, I support debate and initiative.
References
- Stockigt JR. Barriers in the quest for quality drug information: salutary lessons from TGA-approved sources for thyroid-related medications. Med J Aust 2007; 186: 76-79. 0_CHDCBHCE
- Dowden JS. Product information past perfect [editorial]. Med J Aust 2007; 186: 51-52. 0_i1091790
- Therapeutic Goods Administration. Initial discussion paper: improving access to prescription medicines information. Apr 2005. http://www.tga.gov.au/consult/2005/accesspmi.pdf (access Mar 2007).
Still Treating Yesterday's Risk? Reconsidering Antiviral Use for Mild-to-Moderate COVID-19 Cases in a Broadly Immune Population
Hadar Mudrik-Zohar, Tim Cutfield, Susan Morpeth, Thomas Hills, Eamon Duffy, Laura J. Edwards, Allen C. Cheng, Steven Y. C. Tong
Birth prevalence, clinical sequelae, and management of congenital cytomegalovirus infections in Australia, 1999–2023: a national prospective study
Ece Egilmezer, Suzy M Teutsch, Carlos Nunez, Stuart T Hamilton, Adam W Bartlett, Pamela Palasanthiran, Elizabeth J Elliott, William D Rawlinson
Medication delivery and dispensing interval preferences of people who use antihypertensive medications in Australia: a survey study
Carissa Bonner, Michael A Fajardo, Rachael M Keast, Emily Atkins, Niamh Chapman, Kristie R Weir, Anthony Rodgers, Aletta E Schutte
Concurrent use of hormonal long‐acting reversible contraception by women of reproductive age dispensed teratogenic medications, Australia, 2013–2021
Michelle KY Chen, Adrian Lim, Deshan F Sebaratnam
Concurrent use of hormonal long‐acting reversible contraception by women of reproductive age dispensed teratogenic medications, Australia, 2013–2021
Aaron E Boyce, Tony Caccetta, Jo‐Ann See, Rosemary L Nixon AM